-
Je něco špatně v tomto záznamu ?
Curability and transferability of atopy with allogeneic hematopoietic cell transplantation
S. Whiteside, A. Chin, G. Tripathi, P. Dharmani-Khan, M. Markova, P. Keslova, P. Sedlacek, MN. Geddes, V. Lewis, M. Modi, A. Kalra, R. Dabas, A. Akhter, L. Larratt, T. van Slyke, J. Brandwein, SR. Spellman, R. Leigh, A. Daly, FM. Khan, J. Storek
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 1997-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- alergeny MeSH
- časná přecitlivělost * MeSH
- imunoglobulin E MeSH
- lidé MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Atopy is excessive production of IgE in response to allergens. We evaluated in patients undergoing allogeneic hematopoietic cell transplantation (HCT) the following hypotheses: (1) Atopy is "curable" in atopic patients receiving HCT from a nonatopic donor (D-R+), and (2) Atopy is transferable from atopic donors to nonatopic recipients (D+R-). Atopic patients with atopic donors (D+R+) and non-atopic patients with non-atopic donors (D-R-) served as controls. We measured levels of multiallergen-specific IgE (A-IgE, atopy defined as ≥0.35 kUA/L) in sera from 54 patients and their donors pre HCT and from the patients at ≥2 years post HCT. Only 7/12 (58%) D- R+ patients became nonatopic after HCT. Only 1/11 (9%) D+R- patients became atopic. Eleven of 13 (85%) D-R- patients remained nonatopic. Unexpectedly, 11/18 (61%) D+R+ patients became nonatopic. In conclusion, contrary to our hypothesis and previous reports, the "cure" of atopy may occur in only some D-R+ patients and the transfer of atopy may occur rarely. The "cure" may not be necessarily due to the exchange of atopic for nonatopic immune system, as the "cure" may also occur in D+R+ patients.
2nd Faculty of Medicine Charles University Prague Czech Republic
Alberta Health Services Calgary and Edmonton AB Canada
Alberta Public Laboratories Calgary AB Canada
Institute of Hematology and Blood Transfusion Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020372
- 003
- CZ-PrNML
- 005
- 20210830102055.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-020-0876-7 $2 doi
- 035 __
- $a (PubMed)32231249
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Whiteside, Sarah $u University of Calgary, Calgary, AB, Canada. sarah.whiteside1@ucalgary.ca
- 245 10
- $a Curability and transferability of atopy with allogeneic hematopoietic cell transplantation / $c S. Whiteside, A. Chin, G. Tripathi, P. Dharmani-Khan, M. Markova, P. Keslova, P. Sedlacek, MN. Geddes, V. Lewis, M. Modi, A. Kalra, R. Dabas, A. Akhter, L. Larratt, T. van Slyke, J. Brandwein, SR. Spellman, R. Leigh, A. Daly, FM. Khan, J. Storek
- 520 9_
- $a Atopy is excessive production of IgE in response to allergens. We evaluated in patients undergoing allogeneic hematopoietic cell transplantation (HCT) the following hypotheses: (1) Atopy is "curable" in atopic patients receiving HCT from a nonatopic donor (D-R+), and (2) Atopy is transferable from atopic donors to nonatopic recipients (D+R-). Atopic patients with atopic donors (D+R+) and non-atopic patients with non-atopic donors (D-R-) served as controls. We measured levels of multiallergen-specific IgE (A-IgE, atopy defined as ≥0.35 kUA/L) in sera from 54 patients and their donors pre HCT and from the patients at ≥2 years post HCT. Only 7/12 (58%) D- R+ patients became nonatopic after HCT. Only 1/11 (9%) D+R- patients became atopic. Eleven of 13 (85%) D-R- patients remained nonatopic. Unexpectedly, 11/18 (61%) D+R+ patients became nonatopic. In conclusion, contrary to our hypothesis and previous reports, the "cure" of atopy may occur in only some D-R+ patients and the transfer of atopy may occur rarely. The "cure" may not be necessarily due to the exchange of atopic for nonatopic immune system, as the "cure" may also occur in D+R+ patients.
- 650 _2
- $a alergeny $7 D000485
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a časná přecitlivělost $7 D006969
- 650 _2
- $a imunoglobulin E $7 D007073
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chin, Alex $u University of Calgary, Calgary, AB, Canada $u Alberta Public Laboratories, Calgary, AB, Canada
- 700 1_
- $a Tripathi, Gaurav $u University of Calgary, Calgary, AB, Canada $u Alberta Health Services, Calgary and Edmonton, AB, Canada
- 700 1_
- $a Dharmani-Khan, Poonam $u University of Calgary, Calgary, AB, Canada $u Alberta Health Services, Calgary and Edmonton, AB, Canada
- 700 1_
- $a Markova, Marketa $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Keslova, Petra $u 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Sedlacek, Petr $u 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Geddes, Michelle N $u University of Calgary, Calgary, AB, Canada $u Alberta Health Services, Calgary and Edmonton, AB, Canada
- 700 1_
- $a Lewis, Victor $u University of Calgary, Calgary, AB, Canada $u Alberta Health Services, Calgary and Edmonton, AB, Canada
- 700 1_
- $a Modi, Monica $u University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Kalra, Amit $u University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Dabas, Rosy $u University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Akhter, Ariz $u University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Larratt, Loree $u Alberta Health Services, Calgary and Edmonton, AB, Canada $u University of Alberta, Edmonton, AB, Canada
- 700 1_
- $a van Slyke, Tiffany $u Alberta Health Services, Calgary and Edmonton, AB, Canada $u University of Alberta, Edmonton, AB, Canada
- 700 1_
- $a Brandwein, Joseph $u Alberta Health Services, Calgary and Edmonton, AB, Canada $u University of Alberta, Edmonton, AB, Canada
- 700 1_
- $a Spellman, Stephen R $u Immunobiology Research, Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
- 700 1_
- $a Leigh, Richard $u University of Calgary, Calgary, AB, Canada $u Alberta Health Services, Calgary and Edmonton, AB, Canada
- 700 1_
- $a Daly, Andrew $u University of Calgary, Calgary, AB, Canada $u Alberta Health Services, Calgary and Edmonton, AB, Canada
- 700 1_
- $a Khan, Faisal M $u University of Calgary, Calgary, AB, Canada $u Alberta Public Laboratories, Calgary, AB, Canada
- 700 1_
- $a Storek, Jan $u University of Calgary, Calgary, AB, Canada $u Alberta Health Services, Calgary and Edmonton, AB, Canada
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 55, č. 7 (2020), s. 1282-1289
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32231249 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102055 $b ABA008
- 999 __
- $a ok $b bmc $g 1691029 $s 1140818
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 55 $c 7 $d 1282-1289 $e 20200330 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20210728
